Xeris Biopharma Holdings, INC

Xeris Biopharma Holdings, Inc. has concluded privately negotiated exchange transactions and a note conversion, resulting in the retirement of all outstanding 8.00% Convertible Senior Notes due 2028.

Xeris Biopharma Holdings, Inc. announced a private exchange of approximately $23 million in convertible notes for cash and company stock, reducing debt and annual interest payments.

Xeris Biopharma Holdings, Inc. successfully concluded its 2026 Annual Meeting with the election of directors and ratification of its auditor.

Xeris Biopharma announced a 43% year-over-year increase in total product revenue for Q1 2026, reaching over $82 million, and tightened its full-year revenue guidance.

Xeris Biopharma Holdings, Inc. announced that director Dr. Jeffrey Sherman will retire from the Board at the 2026 Annual Meeting.

Xeris Biopharma delivered record Q4 and full-year 2025 revenue, turned profitable, and guided 2026 revenue to $375–$390 million with higher investment in XP-8121 and Recorlev.

Xeris Biopharma Holdings, Inc. announced its first quarter 2026 financial results, showcasing significant revenue growth driven by Recorlev, while managing operational expenses and focusing on pipeline development.

Xeris Biopharma Holdings, Inc. reported a significant increase in total revenue and a shift to positive net income for the third quarter of 2025, driven by robust Recorlev sales.

Xeris Biopharma Holdings, Inc. reported a significant reduction in net loss and strong revenue growth for the second quarter and first half of 2025, driven by increased sales of Recorlev and Gvoke.

Xeris Biopharma's Q1 2025 shows revenue growth driven by key products, with a continued focus on commercialization and pipeline development.

Xeris Biopharma's Q3 2024 results show revenue growth driven by Gvoke and Recorlev, alongside continued investment in their pipeline, particularly XP-8121.

Xeris Biopharma's Q2 2024 results show a 26.5% increase in total revenue compared to Q2 2023, driven primarily by strong growth in Recorlev sales.

Xeris Biopharma Holdings, Inc. reported its first net income since inception in 2025, driven by strong growth in Recorlev sales and overall revenue increase.

Xeris Biopharma's 2024 10-K filing reveals a company focused on commercial growth and strategic partnerships despite ongoing losses and competitive pressures.

Xeris Biopharma's 2023 10-K filing details the company's financial performance, strategic initiatives, and risk factors, emphasizing its focus on commercial growth and innovative product development.

Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 for $8.02 per share.

Beth Hecht, See Remarks of Xeris Biopharma Holdings, Inc., sold 16,666 shares of common stock on August 3, 2026 for $8.01 per share.

Xeris Biopharma Holdings, Inc. (XERS) Chief Financial Officer, Steven Pieper, reported transactions involving the sale of company stock.

Director Nerissa Kreher of Xeris Biopharma Holdings, Inc. acquired 33,582 shares of common stock and 37,910 stock options.

Kevin McCulloch, COO of Xeris Biopharma Holdings, Inc., reported the sale of 90,000 common shares under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock executed under a pre-arranged trading plan.

Xeris Biopharma Holdings announces its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.

Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.

Xeris Biopharma Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.

Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.

Xeris Biopharma Holdings is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the Employee Stock Purchase Plan.

Vanguard Capital Management has reported beneficial ownership of 5% of Xeris Biopharma Holdings Inc. common stock as of June 30, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Xeris Biopharma Holdings Inc. following an internal realignment.

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Xeris Biopharma Holdings Inc.